Redox-Responsive Nanocarrier Based on Heparin End-Capped Mesoporous Silica Nanoparticles for Targeted Tumor Therapy in Vitro and in Vivo
Redox-Responsive Nanocarrier Based on Heparin End-Capped Mesoporous Silica Nanoparticles for Targeted Tumor Therapy in Vitro and in Vivo
复制标题
基于肝素封端介孔二氧化硅纳米粒子的氧化还原响应纳米载体用于体外和体内靶向肿瘤治疗
DOI：
10.1021/la501924p
复制
发表时间：
2014-07-08
期刊：
影响因子：
3.9
通讯作者：
Cai, Kaiyong
中科院分区：
文献类型：
--
作者：
Dai, Liangliang;Li, Jinghua;Cai, Kaiyong
本文报道了一种基于介孔二氧化硅纳米粒子（MSNs）的智能药物控释系统。该系统是通过采用肝素作为封端剂，通过二硫键作为细胞内谷胱甘肽触发的药物释放的中间接头来密封MSN的介孔而制造的。然后将乳糖酸分子偶联至肝素封端的MSN，其用作靶向基序以促进HepG2细胞和肿瘤分别摄取装载阿霉素（DOX）的MSN。详细的研究表明，所制备的药物递送系统可以将DOX递送到体外的癌细胞中以诱导细胞凋亡，并且可以将DOX递送到体内的肿瘤组织中以抑制肿瘤生长，并且副作用最小。该研究提供了一种有前途的纳米载体，用于氧化还原响应的货物递送，具有高的治疗效率，用于癌症治疗。
This study reports a smart controlled drug release system based on mesoporous silica nanoparticles (MSNs) for targeted drug delivery. The system was fabricated by employing heparin as an end-capping agent to seal the mesopores of MSNs via disulfide bonds as intermediate linkers for intracellular glutathione triggered drug release. Lactobionic acid molecules were then coupled to heparin end-capped MSNs that serve as targeting motifs for facilitating the uptake of doxorubicin (DOX) loaded MSNs by HepG2 cells and tumors, respectively. Detailed investigations demonstrated that the fabricated drug delivery systems could deliver DOX to cancer cells to induce cell apoptosis in vitro and tumor tissue for the inhibition of tumor growth in vivo with minimal side effects. The study affords a promising nanocarrier for redox-responsive cargo delivery with high curative efficiency for cancer therapy.